Hepatobiliary contrast agents for Liver Magnetic Resonance Imaging

Radiologia (Engl Ed). 2024 Oct:66 Suppl 2:S75-S88. doi: 10.1016/j.rxeng.2024.05.002. Epub 2024 Oct 21.

Abstract

The use of hepatobiliary-specific contrast agents in liver MRI is a crucial diagnostic tool for evaluating liver disease, enabling the detection and characterisation of focal lesions and vascular alterations, as well as the assessment and grading of chronic hepatopathy. Paramagnetic hepatobiliary-specific contrast agents are gadolinium-based, partially taken up by hepatocytes, and excreted via both renal and biliary pathways. There are two linear ionic molecules that are currently commercially available: gadobenic acid (Gd-BOPTA) and gadoxetic acid (Gd-EOB-DTPA). Their main clinical indications include distinguishing and characterising focal liver lesions on healthy liver tissue, diagnosing and staging hepatocellular carcinoma in patients with chronic hepatopathy, and increasing reliability in the detection of hepatic metastases in oncology patients, especially prior to surgery. They are also useful in the evaluation of the biliary tract and in assessing complications of hepatic surgery such as bile leaks.

Keywords: Contrast media; Gadolinio; Gadolinium; Gd-BOPTA; Gd-EOB-DTPA; Hígado; Liver; Medios de contraste.

MeSH terms

  • Contrast Media*
  • Gadolinium DTPA
  • Humans
  • Liver / diagnostic imaging
  • Liver Diseases* / diagnostic imaging
  • Magnetic Resonance Imaging* / methods
  • Meglumine / analogs & derivatives
  • Organometallic Compounds

Substances

  • Contrast Media
  • gadolinium ethoxybenzyl DTPA
  • Gadolinium DTPA
  • Organometallic Compounds
  • gadobenic acid
  • Meglumine